OR WAIT 15 SECS
AstraZeneca announces that it will invest $285 million in a new manufacturing facility in Sweden.
AstraZeneca announced on May 18, 2015 plans to build a $285 million-manufacturing facility for biological medicines, specifically filling and packaging of protein therapeutics, in Södertälje, Sweden. The investment is the first of a three-part program to expand AstraZeneca’s biologics manufacturing capabilities. AstraZeneca’s largest global tablets and capsules manufacturing facility and launch platform site is also located in Södertälje.
“This is a strategically important investment for AstraZeneca to support the accelerating development of biotech medicines, which now make up around half of our pipeline. We expect to bring a significantly increased number of new specialty care medicines to patients in the coming years, driven in large part by biologics. This new plant will give us greater capacity and flexibility to handle clinical trials, and will also play an important role in our future commercial production,” said Pascal Soriot, CEO of AstraZeneca, in a press release.